View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsChimerix 配当と自社株買い配当金 基準チェック /06Chimerix配当金を支払った記録がありません。主要情報n/a配当利回り-0.9%バイバック利回り総株主利回り-0.9%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Apr 22Chimerix, Inc.(NasdaqGM:CMRX) dropped from NASDAQ Composite IndexChimerix, Inc. has been dropped from the NASDAQ Composite Index.お知らせ • Mar 05Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) entered into a definitive agreement to acquire Chimerix, Inc. (NasdaqGM:CMRX) for approximately $930 million.Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) entered into a definitive agreement to acquire Chimerix, Inc. (NasdaqGM:CMRX) for approximately $930 million on March 4, 2025. Under the terms of the merger agreement, Jazz will commence an all-cash tender offer to acquire all outstanding shares of Chimerix's common stock, whereby Chimerix shareholders will be offered $8.55 per share in cash. Upon the successful completion of the tender offer, Jazz will acquire all shares not acquired in the tender through a second-step merger for the same consideration per share paid in the tender offer. Jazz expects to fund the transaction through existing cash and investments. In case of termination, Chimerix will be required to pay a termination fee of an amount in cash equal to $35,000,000. The transaction is subject to customary closing conditions, including the tender of a majority of the outstanding shares of Chimerix's voting common stock and other conditions. Chimerix's Board of Directors unanimously recommends that Chimerix shareholders tender their shares in the tender offer. The board of directors of Chimerix unanimously approved the agreement. The board of directors of Jazz Pharmaceuticals also approved the agreement and expected to close in the second quarter of 2025. Guggenheim Securities is serving as financial advisor to Jazz Pharmaceuticals, and Mark Gordon and Victor Goldfeld of Wachtell, Lipton, Rosen & Katz is serving as legal advisors. Centerview Partners LLC is serving as financial advisor as well as fairness opinion provider to Chimerix, and Graham Robinson and Laura Knoll of Skadden, Arps, Slate, Meagher & Flom LLP and Jason Kent and Kevin Cooper of Cooley LLP are serving as legal advisors.お知らせ • Feb 18Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse GliomaChimerix announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) seeking accelerated approval for dordaviprone as a treatment for patients with recurrent H3 K27M-mutant diffuse glioma. The application has been granted Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 18, 2025. The FDA does not currently plan to hold an advisory committee meeting to discuss the application. Dordaviprone has received Rare Pediatric Disease Designation for H3 K27M-Mutant diffuse glioma and has applied for a Rare Pediatric Disease Priority Review Voucher (PRV) in the NDA submission. The application remains eligible for this PRV by virtue of its Priority Review status. Dordaviprone also has Fast-Track Designation in the United States and Orphan Drug Designation in the United States, Europe and Australia.お知らせ • Dec 30Chimerix, Inc. Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse GliomaChimerix, Inc. has submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking accelerated approval for dordaviprone as a treatment for patients with recurrent H3 K27M-mutant diffuse glioma in the United States. Chimerix has requested Priority Review for the NDA. If granted, the resulting six-month FDA review period is expected to result in a potential Prescription Drug User Fee Act (PDUFA) action date in the third quarter of 2025. Dordaviprone has received Rare Pediatric Disease Designation for H3 K27M-mutant glioma and has applied for a Rare Pediatric Disease PRV as part of this NDA submission.お知らせ • Dec 10Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-EndChimerix announced that, following extensive dialogue with the U.S. Food and Drug Administration (FDA), the Company plans to submit a complete New Drug Application (NDA) seeking accelerated approval for dordaviprone as a treatment for recurrent H3 K27M-mutant diffuse glioma in the United States before year-end. If successful, dordaviprone would be the first FDA-approved therapy for this lethal disease, as well as one of the first molecularly defined approvals for any high-grade glioma. The following recent program milestones and additional supportive data were extensively discussed with the FDA and will be included in the NDA: Substantial enrollment of the Phase 3 ACTION study; Phase 2 objective response rate of the 50-patient primary efficacy analysis assessed by blinded independent central review (BICR) as the primary basis of efficacy in the NDA; Several response assessments, including the most contemporary response assessment criteria for gliomas, Response Assessment in Neuro-Oncology 2.0 (RANO 2.0), under which dordaviprone demonstrated an objective response rate of 28%, a median duration of response of 10.4 months and a median time to response of 4.6 months; Additional clinical data sets and patient narratives supportive of the primary efficacy analysis; Clinical and nonclinical demonstration of dordaviprone-driven reversal of the central hallmark of H3 K27M-Mutant glioma, H3K27 trimethyl loss; Comprehensive safety database of glioma patients and healthy volunteers that supports a favorable benefit/risk profile; Comprehensive clinical pharmacology and chemistry, manufacturing, and controls (CMC) studies. Chimerix will request Priority Review for the NDA. If granted, the resulting six-month FDA review period is expected to result in a potential initial Prescription Drug User Fee Act (PDUFA) action date in the third quarter of 2025.Reported Earnings • Nov 08Third quarter 2024 earnings released: US$0.26 loss per share (vs US$0.27 loss in 3Q 2023)Third quarter 2024 results: US$0.26 loss per share (improved from US$0.27 loss in 3Q 2023). Net loss: US$22.9m (loss narrowed 4.6% from 3Q 2023). Revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.お知らせ • Nov 01Chimerix, Inc. to Report Q3, 2024 Results on Nov 07, 2024Chimerix, Inc. announced that they will report Q3, 2024 results on Nov 07, 2024Reported Earnings • Aug 14Second quarter 2024 earnings released: US$0.23 loss per share (vs US$0.21 loss in 2Q 2023)Second quarter 2024 results: US$0.23 loss per share (further deteriorated from US$0.21 loss in 2Q 2023). Net loss: US$20.7m (loss widened 11% from 2Q 2023). Revenue is forecast to grow 65% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings.お知らせ • Aug 06Chimerix, Inc. to Report Q2, 2024 Results on Aug 13, 2024Chimerix, Inc. announced that they will report Q2, 2024 results on Aug 13, 2024お知らせ • Jul 05Chimerix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price RequirementOn June 27, 2024, Chimerix, Inc. (the ‘Company’) received a notice from The Nasdaq Global Market (‘Nasdaq’) that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1), as the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days. The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Market. The Company has 180 calendar days, or until December 24, 2024, to regain compliance with the minimum bid price requirement. To regain compliance, the minimum bid price of the Company’s common stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days during this 180-calendar day grace period. In the event the Company does not regain compliance with the minimum bid price requirement by December 24, 2024, the Company may be eligible for an additional 180-calendar day compliance period if it elects to transfer to The Nasdaq Capital Market to take advantage of the additional compliance period offered on that market. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice of its intention to cure the bid price deficiency during the second compliance period. The Company’s failure to regain compliance during this period could result in delisting of its common stock. The Company intends to actively monitor the bid price of its common stock and will consider available options to regain compliance with the listing requirements. There can be no assurance that the Company will be able to regain compliance with Nasdaq’s Listing Rule 5450(a)(1) or will otherwise be in compliance with other Nasdaq listing criteria.Reported Earnings • May 02First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.24 loss in 1Q 2023)First quarter 2024 results: US$0.24 loss per share (further deteriorated from US$0.24 loss in 1Q 2023). Net loss: US$21.9m (loss widened 2.3% from 1Q 2023). Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings.お知らせ • Apr 28Chimerix, Inc., Annual General Meeting, Jun 20, 2024Chimerix, Inc., Annual General Meeting, Jun 20, 2024, at 08:00 Eastern Standard Time. Location: The Umstead Hotel and Spa, located at 100 Woodland Pond Drive Cary North Carolina United States Agenda: To elect each of the Board of Directors’ three nominees, Martha J. Demski, Pratik S. Multani, M.D., and Vicki Vakiener, as a Class II Director, to serve until the 2027 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal; To approve the Company’s 2024 Equity Incentive Plan; to To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024; and to discuss other matters.お知らせ • Apr 26Chimerix, Inc. to Report Q1, 2024 Results on May 01, 2024Chimerix, Inc. announced that they will report Q1, 2024 results on May 01, 2024お知らせ • Mar 21Chimerix Appoints Marc D. Kozin to Board of DirectorsChimerix announced the appointment of Marc D. Kozin as the newest member of the Company’s Board of Directors. In addition, Patrick Machado has announced his retirement from the Chimerix Board effective at the Company’s 2024 Annual Meeting of Stockholders in June, after ten years of service. Mr. Kozin brings more than 35 years of experience in corporate and business strategy consulting, merger and acquisition advisory services, and value management. Mr. Kozin previously served as President of L.E.K., a global strategy consulting firm, where he established the Boston office and led the development of the firm’s industry leading life science strategic planning practice. He currently serves on the Board of Directors of UFP Technologies and HCRx Holdings. Mr. Kozin holds a B.A. in Economics from Duke University and an M.B.A. from The Wharton School, University of Pennsylvania.Reported Earnings • Mar 02Full year 2023 earnings released: US$0.93 loss per share (vs US$1.97 profit in FY 2022)Full year 2023 results: US$0.93 loss per share (down from US$1.97 profit in FY 2022). Net loss: US$82.1m (down 148% from profit in FY 2022). Revenue is forecast to grow 60% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.お知らせ • Feb 23Chimerix, Inc. to Report Q4, 2023 Results on Feb 29, 2024Chimerix, Inc. announced that they will report Q4, 2023 results on Feb 29, 2024お知らせ • Dec 30Chimerix Announces Board ChangesChimerix announced Lisa Decker, Chief Business Officer at IGM Biosciences, has been appointed to Chimerix's Board of Directors. Ms. Decker replaces Catherine Gilliss PhD, RN, FAAN, who is simultaneously retiring from the Chimerix Board after nearly 10 years of service. Prior to her role at IGM Biosciences, Ms. Decker was Chief Business Officer at Atreca Inc., where she oversaw the business development and alliance management functions. Before that, she served in multiple roles at Nektar Therapeutics, most recently serving as Vice President, Business Development. Earlier, she served as Associate Director in the Office of Technology Management at the University of Massachusetts Medical School. Ms. Decker received her Ph.D. in Immunology from Tufts University School of Medicine and her B.A. in Biology from the College of the Holy Cross.お知らせ • Dec 05Chimerix, Inc. Promotes Michelle Laspaluto to the Position of Chief Financial OfficerOn November 29, 2023, the Board of Directors of Chimerix, Inc. promoted Michelle LaSpaluto to the position of Chief Financial Officer of the Company, effective December 1, 2023. Prior to her promotion as the Company's Chief Financial Officer of the Company, Ms. LaSpaluto, age 49, served as the Company's Vice President of Corporate Financial Planning and Investor Relations since October 2019, as Executive Director of Financial Planning, Analysis and Investor Relations from January 2016 to October 2019, and as Senior Director of Accounting from June 2011 to October 2019. Ms. LaSpaluto has over 25 years of experience in a range of financial, accounting, and project planning roles. Prior to joining the Company, Ms. LaSpaluto was the senior director of accounting at AlphaVax, Inc. and started her career at Coopers & Lybrand in Detroit before transferring to Raleigh with PriceWaterhouseCoopers LLP. Ms. LaSpaluto received her M.B.A. from East Carolina University and her B.S. in Accounting from Michigan State University.お知らせ • Nov 17Chimerix, Inc. Appoints Thomas Riga as Chief Operating and Commercial OfficerChimerix, Inc. announced the appointment of Thomas Riga as Chief Operating and Commercial Officer. Prior to joining Chimerix, Mr. Riga served as President and Chief Executive Officer at Spectrum Pharmaceuticals, through its acquisition in July. Prior to being named CEO of Spectrum, Mr. Riga served as the Chief Commercial Officer for nine years and Chief Operating Officer for five years. Before joining Spectrum, he led multiple oncology product teams holding commercial sales and marketing leadership positions at Dendreon, Amgen and Eli Lilly and Company. He began his career at Wyeth Ayerst Laboratories in pharmaceutical manufacturing. Mr. Riga holds a B.S. in Biology and Chemistry from St. Lawrence University.Reported Earnings • Nov 03Third quarter 2023 earnings released: US$0.27 loss per share (vs US$2.75 profit in 3Q 2022)Third quarter 2023 results: US$0.27 loss per share (down from US$2.75 profit in 3Q 2022). Net loss: US$24.0m (down 110% from profit in 3Q 2022). Revenue is forecast to grow 70% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.お知らせ • Oct 27Chimerix, Inc. to Report Q3, 2023 Results on Nov 02, 2023Chimerix, Inc. announced that they will report Q3, 2023 results on Nov 02, 2023New Risk • Oct 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 35% per year for the foreseeable future. Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (€84.7m market cap, or US$89.5m).お知らせ • Aug 17Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to Onc201 Treatment of H3 K27m-Mutant Diffuse Midline Gliomas Published in Cancer DiscoveryChimerix announced the publication of data in support of the Company's first-in-class small molecule impipridone, ONC201, as a treatment for H3 K27M-mutant diffuse midline gliomas (H3K27M-DMG) in the peer-reviewed journal, Cancer Discovery, a journal of the American Association for Cancer Research. The manuscript titled, "Clinical efficacy of ONC201 in H3K27M-mutant diffuse Midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways," reports survival analyses of 71 patients with H3 K27M-DMG treated with ONC201 which demonstrated promising results in a patient population with a poor prognosis and few treatment options. In addition to assessing clinical outcomes, the study corroborated mechanistic findings from laboratory models in samples from treated patients that demonstrated the ability of ONC201 to disrupt metabolic pathways and reverse the epigenetic consequence (H3K27me3-loss) of the H3 K27M mutation.New Risk • Aug 06New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €88.5m (US$97.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 35% per year for the foreseeable future. Minor Risks Share price has been volatile over the past 3 months (7.4% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (€88.5m market cap, or US$97.4m).Reported Earnings • Aug 03Second quarter 2023 earnings released: US$0.21 loss per share (vs US$0.27 loss in 2Q 2022)Second quarter 2023 results: US$0.21 loss per share (improved from US$0.27 loss in 2Q 2022). Revenue: US$26.0k (down 94% from 2Q 2022). Net loss: US$18.6m (loss narrowed 21% from 2Q 2022). Revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.お知らせ • Jul 29Chimerix, Inc. to Report Q2, 2023 Results on Aug 03, 2023Chimerix, Inc. announced that they will report Q2, 2023 results on Aug 03, 2023お知らせ • Jun 28+ 1 more updateChimerix, Inc. Announces Executive Changes, Effective on August 1, 2023Chimerix, Inc. announced the promotion of Mike Andriole, Chief Business Officer and Chief Financial Officer, to President of Chimerix and his appointment to the Board of Directors. Mr. Andriole replaces Mike Sherman, who is retiring from his role as Chief Executive Officer and will become Chairman of the Board of Directors. Martha Demski, the current Board Chair, will assume the role of Lead Independent Director. These appointments will be effective on August 1, 2023. Mr. Andriole joined Chimerix in 2019 as Chief Business Officer and Chief Financial Officer. Since that time, he has supervised strategic planning, new product planning, corporate development, project management, market research, finance and accounting. Prior to joining Chimerix, Mr. Andriole served as Chief Financial Officer of Endocyte, Inc., a clinical- stage biotechnology company developing targeted treatments for prostate and other cancers, where, in partnership with Mr. Sherman, he was instrumental in managing the company through a series of strategic transactions which began at a point in time when the organization had a negative enterprise value and culminated in its sale to Novartis for $2.1 billion. Prior to joining Endocyte, Mr. Andriole spent 16 years at Eli Lilly and Company in a range of financial, marketing and global business development roles, including participation on leadership teams of two commercial product launches which eventually generated more than $5 billion in annual revenue. During his more than 20-year biopharmaceutical career, Mr. Andriole has held leadership roles in the planning, development, or acquisition of nine programs that have garnered regulatory approvals spanning oncology, neuroscience, and infectious disease.Mr. Andriole earned a BSBA from Xavier University'sWilliams College of Business and an MBA from Indiana University'sKelley School of Business.お知らせ • Jun 25Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell 2000 Growth IndexChimerix, Inc.(NasdaqGM:CMRX) dropped from Russell 2000 Growth IndexRecent Insider Transactions • May 18CEO, President & Director recently bought €90k worth of stockOn the 12th of May, Michael Sherman bought around 87k shares on-market at roughly €1.03 per share. This transaction amounted to 36% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months.Reported Earnings • May 05First quarter 2023 earnings released: US$0.24 loss per share (vs US$0.28 loss in 1Q 2022)First quarter 2023 results: US$0.24 loss per share (improved from US$0.28 loss in 1Q 2022). Revenue: US$283.0k (up US$268.0k from 1Q 2022). Net loss: US$21.4m (loss narrowed 14% from 1Q 2022). Revenue is forecast to grow 55% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 03Full year 2022 earnings released: EPS: US$1.97 (vs US$2.04 loss in FY 2021)Full year 2022 results: EPS: US$1.97 (up from US$2.04 loss in FY 2021). Revenue: US$33.8m (up US$31.8m from FY 2021). Net income: US$172.2m (up US$345.4m from FY 2021). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.Board Change • Mar 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Pratik Multani was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Nov 04Third quarter 2022 earnings released: EPS: US$2.75 (vs US$0.21 loss in 3Q 2021)Third quarter 2022 results: EPS: US$2.75 (up from US$0.21 loss in 3Q 2021). Revenue: US$32.6m (up US$32.4m from 3Q 2021). Net income: US$241.4m (up US$259.9m from 3Q 2021). Revenue is expected to decline by 22% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Germany are expected to grow by 21%. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.Breakeven Date Change • Sep 07Forecast to breakeven in 2022The 4 analysts covering Chimerix expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$164.8m in 2022.Reported Earnings • Aug 09Second quarter 2022 earnings released: US$0.27 loss per share (vs US$0.21 loss in 2Q 2021)Second quarter 2022 results: US$0.27 loss per share (down from US$0.21 loss in 2Q 2021). Net loss: US$23.5m (loss widened 32% from 2Q 2021). Over the next year, revenue is forecast to grow 20,015%, compared to a 24% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.Reported Earnings • May 17First quarter 2022 earnings released: US$0.28 loss per share (vs US$1.22 loss in 1Q 2021)First quarter 2022 results: US$0.28 loss per share (up from US$1.22 loss in 1Q 2021). Net loss: US$24.8m (loss narrowed 75% from 1Q 2021). Over the next year, revenue is forecast to grow 18,468%, compared to a 35% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 9% per year, which means it is tracking significantly ahead of earnings growth.Breakeven Date Change • Apr 27No longer forecast to breakevenThe 5 analysts covering Chimerix no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$9.10m in 2024. New consensus forecast suggests the company will make a loss of US$1.43m in 2024.Breakeven Date Change • Mar 05No longer forecast to breakevenThe 5 analysts covering Chimerix no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$9.10m in 2024. New consensus forecast suggests the company will make a loss of US$5.93m in 2024.Reported Earnings • Mar 03Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: US$2.04 loss per share (down from US$0.70 loss in FY 2020). Net loss: US$173.2m (loss widened 298% from FY 2020). Post-clinical trial products Approved (during full year): 1 Revenue missed analyst estimates by 90%. Over the next year, revenue is forecast to grow 4,418%, compared to a 64% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 50% per year, which means it is well ahead of earnings.Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 5 analysts covering Chimerix expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$8.84m in 2024. Average annual earnings growth of 63% is required to achieve expected profit on schedule.Reported Earnings • Nov 05Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.18 loss in 3Q 2020)Third quarter 2021 results: Net loss: US$18.6m (loss widened 63% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings.Breakeven Date Change • Aug 09Forecast to breakeven in 2023The 5 analysts covering Chimerix expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 38% per year to 2022. The company is expected to make a profit of US$10.1m in 2023. Average annual earnings growth of 67% is required to achieve expected profit on schedule.Recent Insider Transactions • Jul 01Independent Director recently bought €65k worth of stockOn the 28th of June, Fred Middleton bought around 10k shares on-market at roughly €6.55 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €77k more in shares than they have sold in the last 12 months.Breakeven Date Change • May 24Forecast to breakeven in 2024The 5 analysts covering Chimerix expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$23.1m in 2024. Average annual earnings growth of 67% is required to achieve expected profit on schedule.Reported Earnings • May 07First quarter 2021 earnings released: US$1.22 loss per share (vs US$0.17 loss in 1Q 2020)First quarter 2021 results: Net loss: US$97.4m (loss widened US$87.0m from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 21% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Feb 28Full year 2020 earnings released: US$0.70 loss per share (vs US$2.03 loss in FY 2019)Full year 2020 results: Net loss: US$43.5m (loss narrowed 61% from FY 2019). Post-clinical trial products Pre-registration: 1 Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth.Analyst Estimate Surprise Post Earnings • Feb 28Revenue misses expectationsRevenue missed analyst estimates by 7.4%. Over the next year, revenue is forecast to grow 421%, compared to a 55% growth forecast for the Biotechs industry in Germany.Is New 90 Day High Low • Feb 17New 90-day high: €8.81The company is up 223% from its price of €2.73 on 19 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 17% over the same period.Is New 90 Day High Low • Jan 27New 90-day high: €7.91The company is up 248% from its price of €2.27 on 29 October 2020. The German market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 17% over the same period.Is New 90 Day High Low • Jan 09New 90-day high: €6.58The company is up 165% from its price of €2.48 on 09 October 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 2.0% over the same period.Is New 90 Day High Low • Dec 08New 90-day high: €3.46The company is up 68% from its price of €2.05 on 09 September 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Nov 11New 90-day high: €2.58The company is up 4.0% from its price of €2.47 on 12 August 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Analyst Estimate Surprise Post Earnings • Nov 06Revenue beats expectationsRevenue exceeded analyst estimates by 11%. Over the next year, revenue is forecast to grow 25%, compared to a 312% growth forecast for the Biotechs industry in Germany.Reported Earnings • Nov 06Third quarter 2020 earnings released: US$0.18 loss per shareThe company reported a decent third quarter result with reduced losses and improved control over expenses, although revenues were weaker. Third quarter 2020 results: Revenue: US$1.61m (down 18% from 3Q 2019). Net loss: US$11.4m (loss narrowed 85% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.お知らせ • Oct 30Chimerix, Inc. to Report Q3, 2020 Results on Nov 05, 2020Chimerix, Inc. announced that they will report Q3, 2020 results at 12:00 PM, GMT Standard Time on Nov 05, 2020お知らせ • Aug 04Chimerix, Inc. to Report Q2, 2020 Results on Aug 10, 2020Chimerix, Inc. announced that they will report Q2, 2020 results at 8:30 AM, US Eastern Standard Time on Aug 10, 2020決済の安定と成長配当データの取得安定した配当: CXFの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: CXFの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Chimerix 配当利回り対市場CXF 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (CXF)n/a市場下位25% (DE)1.5%市場トップ25% (DE)4.5%業界平均 (Biotechs)2.2%アナリスト予想 (CXF) (最長3年)n/a注目すべき配当: CXFは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: CXFは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: CXFの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: CXFが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YDE 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/04/22 20:11終値2025/04/17 00:00収益2024/12/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Chimerix, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。15 アナリスト機関Geoffrey MeachamBarclaysDebjit ChattopadhyayBrean Capital Historical (Janney Montgomery)Ritu BaralCanaccord Genuity12 その他のアナリストを表示
お知らせ • Apr 22Chimerix, Inc.(NasdaqGM:CMRX) dropped from NASDAQ Composite IndexChimerix, Inc. has been dropped from the NASDAQ Composite Index.
お知らせ • Mar 05Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) entered into a definitive agreement to acquire Chimerix, Inc. (NasdaqGM:CMRX) for approximately $930 million.Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) entered into a definitive agreement to acquire Chimerix, Inc. (NasdaqGM:CMRX) for approximately $930 million on March 4, 2025. Under the terms of the merger agreement, Jazz will commence an all-cash tender offer to acquire all outstanding shares of Chimerix's common stock, whereby Chimerix shareholders will be offered $8.55 per share in cash. Upon the successful completion of the tender offer, Jazz will acquire all shares not acquired in the tender through a second-step merger for the same consideration per share paid in the tender offer. Jazz expects to fund the transaction through existing cash and investments. In case of termination, Chimerix will be required to pay a termination fee of an amount in cash equal to $35,000,000. The transaction is subject to customary closing conditions, including the tender of a majority of the outstanding shares of Chimerix's voting common stock and other conditions. Chimerix's Board of Directors unanimously recommends that Chimerix shareholders tender their shares in the tender offer. The board of directors of Chimerix unanimously approved the agreement. The board of directors of Jazz Pharmaceuticals also approved the agreement and expected to close in the second quarter of 2025. Guggenheim Securities is serving as financial advisor to Jazz Pharmaceuticals, and Mark Gordon and Victor Goldfeld of Wachtell, Lipton, Rosen & Katz is serving as legal advisors. Centerview Partners LLC is serving as financial advisor as well as fairness opinion provider to Chimerix, and Graham Robinson and Laura Knoll of Skadden, Arps, Slate, Meagher & Flom LLP and Jason Kent and Kevin Cooper of Cooley LLP are serving as legal advisors.
お知らせ • Feb 18Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse GliomaChimerix announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) seeking accelerated approval for dordaviprone as a treatment for patients with recurrent H3 K27M-mutant diffuse glioma. The application has been granted Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 18, 2025. The FDA does not currently plan to hold an advisory committee meeting to discuss the application. Dordaviprone has received Rare Pediatric Disease Designation for H3 K27M-Mutant diffuse glioma and has applied for a Rare Pediatric Disease Priority Review Voucher (PRV) in the NDA submission. The application remains eligible for this PRV by virtue of its Priority Review status. Dordaviprone also has Fast-Track Designation in the United States and Orphan Drug Designation in the United States, Europe and Australia.
お知らせ • Dec 30Chimerix, Inc. Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse GliomaChimerix, Inc. has submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking accelerated approval for dordaviprone as a treatment for patients with recurrent H3 K27M-mutant diffuse glioma in the United States. Chimerix has requested Priority Review for the NDA. If granted, the resulting six-month FDA review period is expected to result in a potential Prescription Drug User Fee Act (PDUFA) action date in the third quarter of 2025. Dordaviprone has received Rare Pediatric Disease Designation for H3 K27M-mutant glioma and has applied for a Rare Pediatric Disease PRV as part of this NDA submission.
お知らせ • Dec 10Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-EndChimerix announced that, following extensive dialogue with the U.S. Food and Drug Administration (FDA), the Company plans to submit a complete New Drug Application (NDA) seeking accelerated approval for dordaviprone as a treatment for recurrent H3 K27M-mutant diffuse glioma in the United States before year-end. If successful, dordaviprone would be the first FDA-approved therapy for this lethal disease, as well as one of the first molecularly defined approvals for any high-grade glioma. The following recent program milestones and additional supportive data were extensively discussed with the FDA and will be included in the NDA: Substantial enrollment of the Phase 3 ACTION study; Phase 2 objective response rate of the 50-patient primary efficacy analysis assessed by blinded independent central review (BICR) as the primary basis of efficacy in the NDA; Several response assessments, including the most contemporary response assessment criteria for gliomas, Response Assessment in Neuro-Oncology 2.0 (RANO 2.0), under which dordaviprone demonstrated an objective response rate of 28%, a median duration of response of 10.4 months and a median time to response of 4.6 months; Additional clinical data sets and patient narratives supportive of the primary efficacy analysis; Clinical and nonclinical demonstration of dordaviprone-driven reversal of the central hallmark of H3 K27M-Mutant glioma, H3K27 trimethyl loss; Comprehensive safety database of glioma patients and healthy volunteers that supports a favorable benefit/risk profile; Comprehensive clinical pharmacology and chemistry, manufacturing, and controls (CMC) studies. Chimerix will request Priority Review for the NDA. If granted, the resulting six-month FDA review period is expected to result in a potential initial Prescription Drug User Fee Act (PDUFA) action date in the third quarter of 2025.
Reported Earnings • Nov 08Third quarter 2024 earnings released: US$0.26 loss per share (vs US$0.27 loss in 3Q 2023)Third quarter 2024 results: US$0.26 loss per share (improved from US$0.27 loss in 3Q 2023). Net loss: US$22.9m (loss narrowed 4.6% from 3Q 2023). Revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.
お知らせ • Nov 01Chimerix, Inc. to Report Q3, 2024 Results on Nov 07, 2024Chimerix, Inc. announced that they will report Q3, 2024 results on Nov 07, 2024
Reported Earnings • Aug 14Second quarter 2024 earnings released: US$0.23 loss per share (vs US$0.21 loss in 2Q 2023)Second quarter 2024 results: US$0.23 loss per share (further deteriorated from US$0.21 loss in 2Q 2023). Net loss: US$20.7m (loss widened 11% from 2Q 2023). Revenue is forecast to grow 65% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings.
お知らせ • Aug 06Chimerix, Inc. to Report Q2, 2024 Results on Aug 13, 2024Chimerix, Inc. announced that they will report Q2, 2024 results on Aug 13, 2024
お知らせ • Jul 05Chimerix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price RequirementOn June 27, 2024, Chimerix, Inc. (the ‘Company’) received a notice from The Nasdaq Global Market (‘Nasdaq’) that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1), as the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days. The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Market. The Company has 180 calendar days, or until December 24, 2024, to regain compliance with the minimum bid price requirement. To regain compliance, the minimum bid price of the Company’s common stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days during this 180-calendar day grace period. In the event the Company does not regain compliance with the minimum bid price requirement by December 24, 2024, the Company may be eligible for an additional 180-calendar day compliance period if it elects to transfer to The Nasdaq Capital Market to take advantage of the additional compliance period offered on that market. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice of its intention to cure the bid price deficiency during the second compliance period. The Company’s failure to regain compliance during this period could result in delisting of its common stock. The Company intends to actively monitor the bid price of its common stock and will consider available options to regain compliance with the listing requirements. There can be no assurance that the Company will be able to regain compliance with Nasdaq’s Listing Rule 5450(a)(1) or will otherwise be in compliance with other Nasdaq listing criteria.
Reported Earnings • May 02First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.24 loss in 1Q 2023)First quarter 2024 results: US$0.24 loss per share (further deteriorated from US$0.24 loss in 1Q 2023). Net loss: US$21.9m (loss widened 2.3% from 1Q 2023). Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings.
お知らせ • Apr 28Chimerix, Inc., Annual General Meeting, Jun 20, 2024Chimerix, Inc., Annual General Meeting, Jun 20, 2024, at 08:00 Eastern Standard Time. Location: The Umstead Hotel and Spa, located at 100 Woodland Pond Drive Cary North Carolina United States Agenda: To elect each of the Board of Directors’ three nominees, Martha J. Demski, Pratik S. Multani, M.D., and Vicki Vakiener, as a Class II Director, to serve until the 2027 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal; To approve the Company’s 2024 Equity Incentive Plan; to To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024; and to discuss other matters.
お知らせ • Apr 26Chimerix, Inc. to Report Q1, 2024 Results on May 01, 2024Chimerix, Inc. announced that they will report Q1, 2024 results on May 01, 2024
お知らせ • Mar 21Chimerix Appoints Marc D. Kozin to Board of DirectorsChimerix announced the appointment of Marc D. Kozin as the newest member of the Company’s Board of Directors. In addition, Patrick Machado has announced his retirement from the Chimerix Board effective at the Company’s 2024 Annual Meeting of Stockholders in June, after ten years of service. Mr. Kozin brings more than 35 years of experience in corporate and business strategy consulting, merger and acquisition advisory services, and value management. Mr. Kozin previously served as President of L.E.K., a global strategy consulting firm, where he established the Boston office and led the development of the firm’s industry leading life science strategic planning practice. He currently serves on the Board of Directors of UFP Technologies and HCRx Holdings. Mr. Kozin holds a B.A. in Economics from Duke University and an M.B.A. from The Wharton School, University of Pennsylvania.
Reported Earnings • Mar 02Full year 2023 earnings released: US$0.93 loss per share (vs US$1.97 profit in FY 2022)Full year 2023 results: US$0.93 loss per share (down from US$1.97 profit in FY 2022). Net loss: US$82.1m (down 148% from profit in FY 2022). Revenue is forecast to grow 60% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
お知らせ • Feb 23Chimerix, Inc. to Report Q4, 2023 Results on Feb 29, 2024Chimerix, Inc. announced that they will report Q4, 2023 results on Feb 29, 2024
お知らせ • Dec 30Chimerix Announces Board ChangesChimerix announced Lisa Decker, Chief Business Officer at IGM Biosciences, has been appointed to Chimerix's Board of Directors. Ms. Decker replaces Catherine Gilliss PhD, RN, FAAN, who is simultaneously retiring from the Chimerix Board after nearly 10 years of service. Prior to her role at IGM Biosciences, Ms. Decker was Chief Business Officer at Atreca Inc., where she oversaw the business development and alliance management functions. Before that, she served in multiple roles at Nektar Therapeutics, most recently serving as Vice President, Business Development. Earlier, she served as Associate Director in the Office of Technology Management at the University of Massachusetts Medical School. Ms. Decker received her Ph.D. in Immunology from Tufts University School of Medicine and her B.A. in Biology from the College of the Holy Cross.
お知らせ • Dec 05Chimerix, Inc. Promotes Michelle Laspaluto to the Position of Chief Financial OfficerOn November 29, 2023, the Board of Directors of Chimerix, Inc. promoted Michelle LaSpaluto to the position of Chief Financial Officer of the Company, effective December 1, 2023. Prior to her promotion as the Company's Chief Financial Officer of the Company, Ms. LaSpaluto, age 49, served as the Company's Vice President of Corporate Financial Planning and Investor Relations since October 2019, as Executive Director of Financial Planning, Analysis and Investor Relations from January 2016 to October 2019, and as Senior Director of Accounting from June 2011 to October 2019. Ms. LaSpaluto has over 25 years of experience in a range of financial, accounting, and project planning roles. Prior to joining the Company, Ms. LaSpaluto was the senior director of accounting at AlphaVax, Inc. and started her career at Coopers & Lybrand in Detroit before transferring to Raleigh with PriceWaterhouseCoopers LLP. Ms. LaSpaluto received her M.B.A. from East Carolina University and her B.S. in Accounting from Michigan State University.
お知らせ • Nov 17Chimerix, Inc. Appoints Thomas Riga as Chief Operating and Commercial OfficerChimerix, Inc. announced the appointment of Thomas Riga as Chief Operating and Commercial Officer. Prior to joining Chimerix, Mr. Riga served as President and Chief Executive Officer at Spectrum Pharmaceuticals, through its acquisition in July. Prior to being named CEO of Spectrum, Mr. Riga served as the Chief Commercial Officer for nine years and Chief Operating Officer for five years. Before joining Spectrum, he led multiple oncology product teams holding commercial sales and marketing leadership positions at Dendreon, Amgen and Eli Lilly and Company. He began his career at Wyeth Ayerst Laboratories in pharmaceutical manufacturing. Mr. Riga holds a B.S. in Biology and Chemistry from St. Lawrence University.
Reported Earnings • Nov 03Third quarter 2023 earnings released: US$0.27 loss per share (vs US$2.75 profit in 3Q 2022)Third quarter 2023 results: US$0.27 loss per share (down from US$2.75 profit in 3Q 2022). Net loss: US$24.0m (down 110% from profit in 3Q 2022). Revenue is forecast to grow 70% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
お知らせ • Oct 27Chimerix, Inc. to Report Q3, 2023 Results on Nov 02, 2023Chimerix, Inc. announced that they will report Q3, 2023 results on Nov 02, 2023
New Risk • Oct 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 35% per year for the foreseeable future. Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (€84.7m market cap, or US$89.5m).
お知らせ • Aug 17Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to Onc201 Treatment of H3 K27m-Mutant Diffuse Midline Gliomas Published in Cancer DiscoveryChimerix announced the publication of data in support of the Company's first-in-class small molecule impipridone, ONC201, as a treatment for H3 K27M-mutant diffuse midline gliomas (H3K27M-DMG) in the peer-reviewed journal, Cancer Discovery, a journal of the American Association for Cancer Research. The manuscript titled, "Clinical efficacy of ONC201 in H3K27M-mutant diffuse Midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways," reports survival analyses of 71 patients with H3 K27M-DMG treated with ONC201 which demonstrated promising results in a patient population with a poor prognosis and few treatment options. In addition to assessing clinical outcomes, the study corroborated mechanistic findings from laboratory models in samples from treated patients that demonstrated the ability of ONC201 to disrupt metabolic pathways and reverse the epigenetic consequence (H3K27me3-loss) of the H3 K27M mutation.
New Risk • Aug 06New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €88.5m (US$97.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 35% per year for the foreseeable future. Minor Risks Share price has been volatile over the past 3 months (7.4% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (€88.5m market cap, or US$97.4m).
Reported Earnings • Aug 03Second quarter 2023 earnings released: US$0.21 loss per share (vs US$0.27 loss in 2Q 2022)Second quarter 2023 results: US$0.21 loss per share (improved from US$0.27 loss in 2Q 2022). Revenue: US$26.0k (down 94% from 2Q 2022). Net loss: US$18.6m (loss narrowed 21% from 2Q 2022). Revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
お知らせ • Jul 29Chimerix, Inc. to Report Q2, 2023 Results on Aug 03, 2023Chimerix, Inc. announced that they will report Q2, 2023 results on Aug 03, 2023
お知らせ • Jun 28+ 1 more updateChimerix, Inc. Announces Executive Changes, Effective on August 1, 2023Chimerix, Inc. announced the promotion of Mike Andriole, Chief Business Officer and Chief Financial Officer, to President of Chimerix and his appointment to the Board of Directors. Mr. Andriole replaces Mike Sherman, who is retiring from his role as Chief Executive Officer and will become Chairman of the Board of Directors. Martha Demski, the current Board Chair, will assume the role of Lead Independent Director. These appointments will be effective on August 1, 2023. Mr. Andriole joined Chimerix in 2019 as Chief Business Officer and Chief Financial Officer. Since that time, he has supervised strategic planning, new product planning, corporate development, project management, market research, finance and accounting. Prior to joining Chimerix, Mr. Andriole served as Chief Financial Officer of Endocyte, Inc., a clinical- stage biotechnology company developing targeted treatments for prostate and other cancers, where, in partnership with Mr. Sherman, he was instrumental in managing the company through a series of strategic transactions which began at a point in time when the organization had a negative enterprise value and culminated in its sale to Novartis for $2.1 billion. Prior to joining Endocyte, Mr. Andriole spent 16 years at Eli Lilly and Company in a range of financial, marketing and global business development roles, including participation on leadership teams of two commercial product launches which eventually generated more than $5 billion in annual revenue. During his more than 20-year biopharmaceutical career, Mr. Andriole has held leadership roles in the planning, development, or acquisition of nine programs that have garnered regulatory approvals spanning oncology, neuroscience, and infectious disease.Mr. Andriole earned a BSBA from Xavier University'sWilliams College of Business and an MBA from Indiana University'sKelley School of Business.
お知らせ • Jun 25Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell 2000 Growth IndexChimerix, Inc.(NasdaqGM:CMRX) dropped from Russell 2000 Growth Index
Recent Insider Transactions • May 18CEO, President & Director recently bought €90k worth of stockOn the 12th of May, Michael Sherman bought around 87k shares on-market at roughly €1.03 per share. This transaction amounted to 36% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months.
Reported Earnings • May 05First quarter 2023 earnings released: US$0.24 loss per share (vs US$0.28 loss in 1Q 2022)First quarter 2023 results: US$0.24 loss per share (improved from US$0.28 loss in 1Q 2022). Revenue: US$283.0k (up US$268.0k from 1Q 2022). Net loss: US$21.4m (loss narrowed 14% from 1Q 2022). Revenue is forecast to grow 55% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 03Full year 2022 earnings released: EPS: US$1.97 (vs US$2.04 loss in FY 2021)Full year 2022 results: EPS: US$1.97 (up from US$2.04 loss in FY 2021). Revenue: US$33.8m (up US$31.8m from FY 2021). Net income: US$172.2m (up US$345.4m from FY 2021). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
Board Change • Mar 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Pratik Multani was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Nov 04Third quarter 2022 earnings released: EPS: US$2.75 (vs US$0.21 loss in 3Q 2021)Third quarter 2022 results: EPS: US$2.75 (up from US$0.21 loss in 3Q 2021). Revenue: US$32.6m (up US$32.4m from 3Q 2021). Net income: US$241.4m (up US$259.9m from 3Q 2021). Revenue is expected to decline by 22% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Germany are expected to grow by 21%. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
Breakeven Date Change • Sep 07Forecast to breakeven in 2022The 4 analysts covering Chimerix expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$164.8m in 2022.
Reported Earnings • Aug 09Second quarter 2022 earnings released: US$0.27 loss per share (vs US$0.21 loss in 2Q 2021)Second quarter 2022 results: US$0.27 loss per share (down from US$0.21 loss in 2Q 2021). Net loss: US$23.5m (loss widened 32% from 2Q 2021). Over the next year, revenue is forecast to grow 20,015%, compared to a 24% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
Reported Earnings • May 17First quarter 2022 earnings released: US$0.28 loss per share (vs US$1.22 loss in 1Q 2021)First quarter 2022 results: US$0.28 loss per share (up from US$1.22 loss in 1Q 2021). Net loss: US$24.8m (loss narrowed 75% from 1Q 2021). Over the next year, revenue is forecast to grow 18,468%, compared to a 35% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 9% per year, which means it is tracking significantly ahead of earnings growth.
Breakeven Date Change • Apr 27No longer forecast to breakevenThe 5 analysts covering Chimerix no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$9.10m in 2024. New consensus forecast suggests the company will make a loss of US$1.43m in 2024.
Breakeven Date Change • Mar 05No longer forecast to breakevenThe 5 analysts covering Chimerix no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$9.10m in 2024. New consensus forecast suggests the company will make a loss of US$5.93m in 2024.
Reported Earnings • Mar 03Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: US$2.04 loss per share (down from US$0.70 loss in FY 2020). Net loss: US$173.2m (loss widened 298% from FY 2020). Post-clinical trial products Approved (during full year): 1 Revenue missed analyst estimates by 90%. Over the next year, revenue is forecast to grow 4,418%, compared to a 64% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 50% per year, which means it is well ahead of earnings.
Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 5 analysts covering Chimerix expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$8.84m in 2024. Average annual earnings growth of 63% is required to achieve expected profit on schedule.
Reported Earnings • Nov 05Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.18 loss in 3Q 2020)Third quarter 2021 results: Net loss: US$18.6m (loss widened 63% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings.
Breakeven Date Change • Aug 09Forecast to breakeven in 2023The 5 analysts covering Chimerix expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 38% per year to 2022. The company is expected to make a profit of US$10.1m in 2023. Average annual earnings growth of 67% is required to achieve expected profit on schedule.
Recent Insider Transactions • Jul 01Independent Director recently bought €65k worth of stockOn the 28th of June, Fred Middleton bought around 10k shares on-market at roughly €6.55 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €77k more in shares than they have sold in the last 12 months.
Breakeven Date Change • May 24Forecast to breakeven in 2024The 5 analysts covering Chimerix expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$23.1m in 2024. Average annual earnings growth of 67% is required to achieve expected profit on schedule.
Reported Earnings • May 07First quarter 2021 earnings released: US$1.22 loss per share (vs US$0.17 loss in 1Q 2020)First quarter 2021 results: Net loss: US$97.4m (loss widened US$87.0m from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 21% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Feb 28Full year 2020 earnings released: US$0.70 loss per share (vs US$2.03 loss in FY 2019)Full year 2020 results: Net loss: US$43.5m (loss narrowed 61% from FY 2019). Post-clinical trial products Pre-registration: 1 Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth.
Analyst Estimate Surprise Post Earnings • Feb 28Revenue misses expectationsRevenue missed analyst estimates by 7.4%. Over the next year, revenue is forecast to grow 421%, compared to a 55% growth forecast for the Biotechs industry in Germany.
Is New 90 Day High Low • Feb 17New 90-day high: €8.81The company is up 223% from its price of €2.73 on 19 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 17% over the same period.
Is New 90 Day High Low • Jan 27New 90-day high: €7.91The company is up 248% from its price of €2.27 on 29 October 2020. The German market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 17% over the same period.
Is New 90 Day High Low • Jan 09New 90-day high: €6.58The company is up 165% from its price of €2.48 on 09 October 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 2.0% over the same period.
Is New 90 Day High Low • Dec 08New 90-day high: €3.46The company is up 68% from its price of €2.05 on 09 September 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Nov 11New 90-day high: €2.58The company is up 4.0% from its price of €2.47 on 12 August 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Analyst Estimate Surprise Post Earnings • Nov 06Revenue beats expectationsRevenue exceeded analyst estimates by 11%. Over the next year, revenue is forecast to grow 25%, compared to a 312% growth forecast for the Biotechs industry in Germany.
Reported Earnings • Nov 06Third quarter 2020 earnings released: US$0.18 loss per shareThe company reported a decent third quarter result with reduced losses and improved control over expenses, although revenues were weaker. Third quarter 2020 results: Revenue: US$1.61m (down 18% from 3Q 2019). Net loss: US$11.4m (loss narrowed 85% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
お知らせ • Oct 30Chimerix, Inc. to Report Q3, 2020 Results on Nov 05, 2020Chimerix, Inc. announced that they will report Q3, 2020 results at 12:00 PM, GMT Standard Time on Nov 05, 2020
お知らせ • Aug 04Chimerix, Inc. to Report Q2, 2020 Results on Aug 10, 2020Chimerix, Inc. announced that they will report Q2, 2020 results at 8:30 AM, US Eastern Standard Time on Aug 10, 2020